How India Is Strengthening Its API Manufacturing and Pharmaceutical Supply Chain

 Introduction

India is entering an important phase in pharmaceutical manufacturing, with increasing attention on domestic API production, supply chain resilience, advanced manufacturing and global competitiveness. Active Pharmaceutical Ingredients, or APIs, are the key substances responsible for the therapeutic action of medicines. Their availability directly influences the production of finished pharmaceutical formulations.

India has traditionally been a major global pharmaceutical manufacturing hub, but dependence on imported APIs, Key Starting Materials (KSMs) and Drug Intermediates (DIs) has highlighted the need for a stronger domestic supply base. In response, the Indian government has introduced several initiatives designed to expand local manufacturing capacity and reduce supply vulnerabilities. As of December 2025, 38 projects covering 28 notified products had been commissioned under the PLI scheme for bulk drugs, creating approximately 56,800 tonnes per year of domestic manufacturing capacity. 

Increasing Domestic API Manufacturing Capacity

Strengthening domestic API manufacturing is one of India's major pharmaceutical priorities. The Production Linked Incentive scheme for Bulk Drugs was established with a ₹6,940 crore outlay to encourage manufacturing of critical KSMs, DIs and APIs that had significant import dependence.

The progress is becoming increasingly visible. Government data shows that ₹4,814 crore had been invested under the bulk drug PLI scheme by December 2025, while production capacity had been created for 26 critical KSMs, DIs and APIs. 

This expansion can provide pharmaceutical manufacturers with additional domestic sourcing options and contribute to a more diversified raw material ecosystem.

Government Initiatives Supporting Pharmaceutical Self Reliance

Government policy is playing an important role in transforming India's pharmaceutical supply chain. The objective is not simply to increase the number of manufacturing facilities but to establish capabilities for strategically important pharmaceutical inputs.

Several initiatives are contributing to this direction:

• The Bulk Drug PLI scheme supports domestic production of critical APIs, KSMs and DIs. 

• The PLI Scheme for Pharmaceuticals encourages investment in higher value pharmaceutical products. 

• Three Bulk Drug Parks have been approved in Andhra Pradesh, Gujarat and Himachal Pradesh. 

• The PRIP scheme is supporting pharmaceutical research, innovation and product development. 

These programs can help build stronger manufacturing infrastructure while encouraging investment in areas that are important to India's long term pharmaceutical capabilities.

Building a More Resilient Pharmaceutical Supply Chain

Supply chain resilience has become a major consideration for pharmaceutical companies. Disruptions affecting raw materials can influence manufacturing schedules, inventory planning and ultimately the availability of finished medicines.

India's approach is increasingly focused on reducing excessive dependence on single sources for critical pharmaceutical inputs. The Bulk Drug PLI scheme specifically targets products where supply disruption could create challenges for essential medicines. 

For pharmaceutical businesses, a resilient supply chain can involve domestic sourcing, multiple qualified suppliers, appropriate inventory planning and stronger coordination between manufacturers and distributors.

This changing environment is creating opportunities for Indian API producers and pharmaceutical suppliers that can support consistent sourcing requirements.

Technology and Innovation Are Shaping the Next Stage

Expanding production capacity is only one part of India's pharmaceutical development. Modern API manufacturing also requires efficient processes, sophisticated analytical capabilities and appropriate quality systems.

Technology can contribute to areas such as:

• Process monitoring and automation 

• Advanced analytical testing 

• Production data management 

• Process optimization 

• Manufacturing efficiency 

• Quality control and documentation 

India is also moving toward higher value pharmaceutical manufacturing. The pharmaceutical PLI scheme supports products such as biopharmaceuticals, complex generic medicines and other high value segments. The government has also established Centres of Excellence through the PRIP initiative to strengthen pharmaceutical research and innovation. 

This transition can encourage manufacturers to combine traditional pharmaceutical expertise with modern production and research capabilities.

Bulk Drug Parks Can Strengthen the Manufacturing Ecosystem

India's Bulk Drug Park initiative represents another significant development in strengthening pharmaceutical infrastructure. Three parks have been approved in Gujarat, Andhra Pradesh and Himachal Pradesh, with central assistance intended to support common infrastructure facilities. 

Shared infrastructure can be particularly valuable for chemical and pharmaceutical manufacturing because facilities may require specialized utilities, waste management systems and other supporting infrastructure.

The development of these parks can help create concentrated manufacturing ecosystems where pharmaceutical companies, raw material producers and supporting industries operate within a connected industrial environment.

For India, such infrastructure could contribute to improved production efficiency and help strengthen domestic capabilities across different stages of the pharmaceutical supply chain.

India’s Global Pharmaceutical Position Is Evolving

India already has an established presence in international pharmaceutical markets. The country has a large API and generic medicine manufacturing base and supplies pharmaceutical products to markets across the world. Invest India reports that India accounts for about 8% of global API manufacturing and produces more than 500 APIs. 

The next opportunity is to strengthen India's position further by combining manufacturing scale with supply chain reliability, innovation and product diversification.

Indian pharmaceutical manufacturers are increasingly looking beyond traditional production models. Higher value products, specialty pharmaceutical ingredients, complex medicines and advanced manufacturing technologies can create new opportunities in international markets.

As global pharmaceutical companies continue evaluating diversified sourcing strategies, India's expanding domestic API capabilities could become an increasingly important part of international supply networks.

Conclusion

India's API manufacturing sector is undergoing an important transformation. Government initiatives, increased domestic production, pharmaceutical infrastructure, technological development and research programs are collectively supporting a stronger pharmaceutical supply chain.

As global pharmaceutical companies continue to diversify their sourcing strategies, India's growing manufacturing capabilities could create new opportunities across APIs, pharmaceutical intermediates, specialty chemicals and finished pharmaceutical products.

For pharmaceutical manufacturers, procurement teams and distributors looking for products and supply opportunities from India, Kavya Pharma can be considered as a potential industry partner. With India's pharmaceutical ecosystem continuing to develop, companies connected to this expanding supply network can participate in the country's growing role in global pharmaceutical manufacturing.

.

For More Information:

Call: +91 7567426252

Address: Kavya Pharma, Shop No.215, Raj Mandir Complex, Aai Mata Road, Parvat Patiya, Surat, Gujarat-395010

Email: sales@kavyapharma.com

Website: www.kavyapharma.com